Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels

References

• Tana C, Umesaki Y, Imaoka A, et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22:512–519, e114–e115.
   PubMed Web of Science ®Google Scholar
• Sisson G, Ayis S, Sherwood RA, et al. Randomised clinical trial: a liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome—A 12 week double-blind study. Aliment Pharmacol Ther. 2014;40:51–62.
   PubMed Web of Science ®Google Scholar
• Menees SB, Maneerattannaporn M, Kim HM, et al. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107:28–35.
   PubMed Web of Science ®Google Scholar
• Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol. 2013;29:79–84.
   PubMed Web of Science ®Google Scholar
• van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–415.
   PubMed Web of Science ®Google Scholar
• Pinn DM, Aroniadis OC, Brandt LJ. Is fecal microbiota transplantation the answer for irritable bowel syndrome? A single-center experience. Am J Gastroenterol. 2014;109:1831–1832.
   PubMed Web of Science ®Google Scholar
• Holvoet T, Joossens M, Wang J, et al. Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating. Gut. 2017;66:980–982.
   PubMed Web of Science ®Google Scholar
• Johnsen PH, Hilpusch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018;3:17–24.
   PubMed Web of Science ®Google Scholar
• Mazzawi T, Lied GA, Sangnes DA, et al. The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation. PLoS One. 2018;13:e0194904.
   PubMed Web of Science ®Google Scholar
• Halkjaer SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67:2107–2115.
   PubMed Web of Science ®Google Scholar
• Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev. 2001;81:1031–1064.
   PubMed Web of Science ®Google Scholar
• Mortensen PB, Andersen JR, Arffmann S, et al. Short-chain fatty acids and the irritable bowel syndrome: the effect of wheat bran. Scand J Gastroenterol. 1987;22:185–192.
   PubMed Web of Science ®Google Scholar
• Ahmed I, Greenwood R, Costello Bde L, et al. An investigation of fecal volatile organic metabolites in irritable bowel syndrome. PLoS One. 2013;8:e58204.
   PubMed Web of Science ®Google Scholar
• Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11:395–402.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66:569–580.
   PubMed Web of Science ®Google Scholar
• Zijlstra JB, Beukema J, Wolthers BG, et al. Pretreatment methods prior to gaschromatographic analysis of volatile fatty acids from faecal samples. Clin Chim Acta. 1977;78:243–250.
   PubMed Web of Science ®Google Scholar
• Hoverstad T, Fausa O, Bjorneklett A, et al. Short-chain fatty acids in the normal human feces. Scand J Gastroenterol. 1984;19:375–381.
   PubMed Web of Science ®Google Scholar
• Kozich JJ, Westcott SL, Baxter NT, et al. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol. 2013;79:5112–5120.
   PubMed Web of Science ®Google Scholar
• Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7:335–336.
   PubMed Web of Science ®Google Scholar
• Shannon CE. A mathematical theory of communication. Bell Syst Tech J. 1948;27:379–423.
   Web of Science ®Google Scholar
• Chiu CH, Wang YT, Walther BA, et al. An improved nonparametric lower bound of species richness via a modified good-turing frequency formula. Biometrics. 2014;70:671–682.
   PubMed Web of Science ®Google Scholar
• Chao A. Nonparametric estimation of the number of classes in a population. Scand J Stat. 1984;11:265–270.
   Web of Science ®Google Scholar
• Mathias JR, Clench MH, Reeves-Darby VG, et al. Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Double-blind, placebo-controlled study. Digest Dis Sci. 1994;39:1155–1162.
   PubMed Web of Science ®Google Scholar
• Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003;98:1309–1314.
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920–924.
   PubMed Web of Science ®Google Scholar
• Arslan G, Lind R, Olafsson S, et al. Quality of life in patients with subjective food hypersensitivity: applicability of the 10-item short form of the Nepean Dyspepsia Index. Dig Dis Sci. 2004;49:680–687.
   PubMed Web of Science ®Google Scholar
• World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. Jahrbuch Für Wissenschaft Und Ethik. 2009;14:233–238.
   Google Scholar
• Hamer HM, Jonkers D, Venema K, et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27:104–119.
   PubMed Web of Science ®Google Scholar
• Farup PG, Rudi K, Hestad K. Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome? BMC Gastroenterol. 2016;16:51.
   PubMed Web of Science ®Google Scholar
• Halmos EP, Christophersen CT, Bird AR, et al. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015;64:93–100.
   PubMed Web of Science ®Google Scholar
• Mizuno S, Masaoka T, Naganuma M, et al. Bifidobacterium-rich fecal donor may be a positive predictor for successful fecal microbiota transplantation in patients with irritable bowel syndrome. Digestion. 2017;96:29–38.
   PubMed Web of Science ®Google Scholar
• Bennet SM, Ohman L, Simren M. Gut microbiota as potential orchestrators of irritable bowel syndrome. Gut Liver. 2015;9:318–331.
   PubMed Web of Science ®Google Scholar
• Chang C, Lin H. Dysbiosis in gastrointestinal disorders. Best Pract Res Clin Gastroenterol. 2016;30:3–15.
   PubMed Web of Science ®Google Scholar
• Riviere A, Selak M, Lantin D, et al. Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front Microbiol. 2016;7:979.
   PubMed Web of Science ®Google Scholar
• Nakanishi N, Tashiro K, Kuhara S, et al. Regulation of virulence by butyrate sensing in enterohaemorrhagic Escherichia coli. Microbiology (Reading, England). 2009;155:521–530.
   PubMed Web of Science ®Google Scholar
• Gorkiewicz G, Thallinger GG, Trajanoski S, et al. Alterations in the colonic microbiota in response to osmotic diarrhea. PLoS One. 2013;8:e55817.
   PubMed Web of Science ®Google Scholar
• Gomes TA, Elias WP, Scaletsky IC, et al. Diarrheagenic Escherichia coli. Braz J Microbiol. 2016;47:3–30.
   PubMed Web of Science ®Google Scholar
• Cani PD, de Vos WM. Next-generation beneficial microbes: the case of Akkermansia muciniphila. Front Microbiol. 2017;8:1765.
   PubMed Web of Science ®Google Scholar
• Crost EH, Tailford LE, Monestier M, et al. The mucin-degradation strategy of Ruminococcus gnavus: the importance of intramolecular trans-sialidases. Gut Microbes. 2016;7:302–312.
   PubMed Web of Science ®Google Scholar
• Png CW, Linden SK, Gilshenan KS, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol. 2010;105:2420–2428.
   PubMed Web of Science ®Google Scholar
• Tap J, Derrien M, Tornblom H, et al. Identification of an Intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017;152:111–123.e8.
   PubMed Web of Science ®Google Scholar
• Vandeputte D, Falony G, Vieira-Silva S, et al. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016;65:57–62.
   PubMed Web of Science ®Google Scholar
• Heaton KW, Radvan J, Cripps H, et al. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut. 1992;33:818–824.
   PubMed Web of Science ®Google Scholar
• Zhang F, Cui B, He X, et al. Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell. 2018;9:462–473.
   PubMed Web of Science ®Google Scholar
• Hamilton MJ, Weingarden AR, Sadowsky MJ, et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107:761–767.
   PubMed Web of Science ®Google Scholar
• Xu D, Chen VL, Steiner CA, et al. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2019;1.
   Google Scholar
• Tan J, McKenzie C, Potamitis M, et al. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91–119.
   PubMed Web of Science ®Google Scholar